<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <Volume-Issue>Volume 2; Issue 5</Volume-Issue>
      <Season>(Sep-Oct, 2021)</Season>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Lamotrigine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Masquerading as A Systemic Autoimmune Process</ArticleTitle>
      <Abstract>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a syndrome that is the consequence of a hypersensitivity reaction associated with exposure to certain medications in a population of individuals with presumed genetic predisposition to certain drugs. It is a potentially life-threatening condition that presents with rash and multi-organ system involvement. While characteristic findings include eosinophilia, lymphocytosis, and lymphadenopathy (LAD), clinical and pathological features can vary significantly. Aside from the observed immune response to certain drugs, its pathogenesis also includes reactivation of latent Herpesviridae. This suggests that drug exposure alone may not elicit the syndrome if neither active or latent Herpesviridae are present, Drug-induced hypersensitivity syndrome (DIHS) is postulated to be a consequence of the interplay between drug exposure and viral infection (latent or otherwise). With a mortality rate of approximately 10%, timely recognition and treatment is imperative. This end can only be accomplished through greater familiarity with the clinical features of DRESS/DIHS. We present a case report of a 35-year-old woman with fever, rash, and lymphadenopathy suffering from lamotrigine-associated DRESS/DIHS masquerading as a systemic autoimmune process.</Abstract>
      <Keywords>Drug Reaction,Eosinophilia,Systemic Symptoms,Drug-Induced Hypersensitivity Syndrome,Lamotrigine,Lamictal,Regiscar,Cervical Lymphadenopathy</Keywords>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13271&amp;title=Lamotrigine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Masquerading as A Systemic Autoimmune Process</Abstract>
        <References>Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250-257.&#13;
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. Am J Med 2011; 124: 588-597.&#13;
Chiou CC, Yang LC, Hung SI, Chang YC, Kuo TT, Ho HC, Hu S, Hong HS, Chung WH. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol 2008; 22: 1044-1049.&#13;
Cho YT, Yang CW, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. Int J Mol Sci 2017; 18: 1243.&#13;
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol 2013; 68: 709.e1-720.&#13;
Miyagawa F, Nakamura Y, Miyashita K, Iioka H, Himuro Y, Ogawa K, Nishimura C, Nishikawa M, Mitsui Y, Ito Y, Ommori R. Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS). J Dermatol Sci 2016; 83: 151-154.&#13;
Myers GB, Heide ECV, Balcerski M. Exfoliative Dermatitis Following Sulfanilamide. JAMA 1937; 109: 1983–1984.&#13;
Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, Hillaire?Buys D, Network of the French Pharmacovigilance Centers. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155: 422-428.&#13;
Schlienger RG, Knowles SR, Shear NH. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998; 51: 1172-1175.&#13;
Shear NH and Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826-1832.&#13;
Singer JZ and Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-87.</References>